UNIVERSITAET zu LUEBECK

Their core work

University of Lübeck is a German research university with deep strengths in neuroscience, biomedical imaging, and computational medicine. They develop advanced optical and endoscopic imaging technologies (OCT, multiphoton microscopy), investigate neurological and neuroendocrine disorders (Parkinson's, Alzheimer's, auditory aging), and contribute to digital health interoperability and AI systems. Their work bridges fundamental brain research with clinical diagnostics and therapeutic development, including antiviral drug discovery and complement system immunology.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Lübeck focused on robotics, bio-hybrid architectures, applied mathematics, and Industry 4.0 digitalization — a broad, exploratory portfolio spanning cognitive robotics (flora robotica), brain imaging (Lifebrain), and smart production (Productive4.0). From 2019 onward, their work shifted decisively toward biomedical and clinical research: complement immunology (CORVOS), antiviral therapeutics (SCORE, CARE, CM_GF), neuroendocrine disorders (WATCH, miniNO), and advanced medical imaging (NETLAS, FAIR CHARM). The digital strand narrowed from general Industry 4.0 toward health-specific applications like cancer survivorship interoperability (PanCareSurPass) and trustworthy AI for medical contexts (DAIS).

Lübeck is consolidating around translational biomedical research — particularly neuroendocrine disorders, advanced optical diagnostics, and therapeutic immunology — making them a strong partner for health-focused consortia through 2027 and beyond.

How they like to work

Lübeck balances leadership and partnership effectively: they coordinated 8 of 30 projects (27%), mostly in their core strengths of imaging, neuroscience, and mathematics, while joining larger consortia as a specialist partner in health and digital projects. With 455 unique consortium partners across 35 countries, they operate as a well-connected hub rather than a closed network. Their willingness to participate as a third party in select projects (GOAL-Robots, IDEA-FAST, NeutroCure) signals openness to contributing focused expertise without needing a lead role.

Highly connected across Europe with 455 distinct consortium partners spanning 35 countries. This breadth indicates a university that is sought after by diverse consortia rather than locked into a single regional cluster.

What sets them apart

Lübeck's defining strength is its ability to connect advanced physics-based imaging technology with clinical neuroscience and immunology research — a rare combination in a mid-sized German university. Where larger institutions spread thin, Lübeck concentrates on the intersection of optical diagnostics, brain disorders, and therapeutic development, giving them end-to-end capability from instrument design to clinical validation. Their mathematical foundations (spectral theory, approximation methods) underpin this imaging work, creating a technically rigorous pipeline that few competitors can match.

Highlights from their portfolio

• WATCH
  Largest single grant (EUR 2.875M) funding a decade-long study (2019–2026) on hypothalamic control of aging — signals deep institutional commitment to neuroendocrine research.
• ENCOMOLE-2i
  Coordinated this EUR 2M project on endoscopic multimodal molecular imaging, representing the convergence of their optical physics and clinical diagnostics strengths.
• flora robotica
  An unusually creative project coordinated by Lübeck — symbiotic robot-plant bio-hybrids as architectural artifacts — showcasing their capacity for interdisciplinary, boundary-pushing research.